Denali Advisors LLC Grows Position in Johnson & Johnson (NYSE:JNJ)

Denali Advisors LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 5,128 shares of the company’s stock after acquiring an additional 67 shares during the quarter. Denali Advisors LLC’s holdings in Johnson & Johnson were worth $742,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. IFS Advisors LLC increased its position in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares during the period. Highline Wealth Partners LLC bought a new stake in shares of Johnson & Johnson during the third quarter valued at about $31,000. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $32,000. RPg Family Wealth Advisory LLC bought a new stake in shares of Johnson & Johnson during the third quarter valued at about $35,000. Finally, Activest Wealth Management bought a new stake in shares of Johnson & Johnson during the third quarter valued at about $40,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the topic of several analyst reports. Morgan Stanley decreased their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Raymond James decreased their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Finally, Leerink Partners decreased their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $170.67.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.9 %

JNJ stock opened at $165.23 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a market capitalization of $397.81 billion, a PE ratio of 24.85, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The company’s 50 day moving average price is $150.90 and its two-hundred day moving average price is $156.06.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the business earned $2.29 earnings per share. The business’s revenue was up 5.3% on a year-over-year basis. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.00%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.